Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03076385 | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | PHASE1 | COMPLETED | 201 | — | — | Dec 1, 2015 | Oct 1, 2018 | Apr 22, 2022 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| VAL-506440 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VAL-506440 | BIOLOGICAL | Escalating dose levels |
| Placebo | OTHER | - |
Inclusion * Agrees to comply with the study procedures and provides written informed consent * 18 to 64 years of age * Body mass index between 18 and 30 kg/m2 * Negative urine pregnancy test at the Screening visit and the day of each vaccination. * Female subjects must either be of non-childbearing...